Comparative Pharmacology
Head-to-head clinical analysis: FIRAZYR versus ICATIBANT ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIRAZYR versus ICATIBANT ACETATE.
FIRAZYR vs ICATIBANT ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Icatibant is a selective antagonist of the bradykinin B2 receptor, blocking the binding of bradykinin and thereby inhibiting the increased vascular permeability and vasodilation that underlie acute attacks of hereditary angioedema (HAE).
Competitive antagonist of bradykinin B2 receptors, inhibiting bradykinin-mediated vasodilation, increased vascular permeability, and pain signaling. Also inhibits bradykinin-induced release of tissue plasminogen activator.
30 mg subcutaneously every 3 days. For acute attacks, 30 mg subcutaneously as needed, not to exceed 3 doses in 24 hours.
30 mg subcutaneous injection (pre-filled syringe) at the first sign of an acute attack; may repeat every 6 hours as needed, not to exceed 3 doses in 24 hours.
None Documented
None Documented
Terminal half-life approximately 1.5 hours; clinically, effects last longer due to receptor binding kinetics.
Terminal elimination half-life approximately 1-2 hours in healthy adults, supporting intermittent intravenous dosing every 6 hours.
Primarily metabolized in the liver (hydrolysis by peptidases); renal excretion of metabolites (approximately 25% unchanged drug in urine). Less than 10% excreted in feces.
Primarily renal: 40% unchanged drug; 40% as inactive metabolites; biliary/fecal <10%.
Category C
Category C
Bradykinin B2 Receptor Antagonist
Bradykinin B2 Receptor Antagonist